1
Home
Companies

Evaxion Biotech

Evaxion Biotech
Leadership team

Dr. Niels Iversen Moeller M.D. (Co-Founder, VP of Bus. & Director)

Mr. Andreas Holm Mattsson (Co-Founder and Chief AI & Culture Officer)

Dr. Birgitte Rono Ph.D. (Chief Scientific Officer)

Products/ Services
Biotechnology
Number of Employees
50 - 100
Headquarters
Copenhagen, Hovedstaden, Denmark
Established
2008
Company Registration
SEC CIK number: 0001828253
Traded as
NASDAQ:EVAX
Social Media
URL
https://www.evaxion-biotech.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
History

Evaxion Biotech was founded in 2015 by scientists Sven Hanson and Jenny Nordvall. With the help of a team of experienced researchers, we have continued to investigate and develop innovative solutions for therapeutic treatments.

Mission
Our mission is to use our expertise to reduce the burden of disease on human and animal health and to improve the quality of life of our patients.
Vision
Our vision is to become the global leader in developing safe, innovative and effective therapeutic solutions for the medical challenges of our times.
Key Team

Dr. Erik Deichmann Heegaard DMSC, M.D., Ph.D. (Chief Medical Officer)

Dr. Per Norlen (Chief Exec. Officer)

Mr. Bo Lokke Karmark (Chief Financial Officer)

Mr. Jesper Nyegaard Nissen (Chief Operating Officer)

Dr. Jürgen Langhärig EMBA, Ph.D. (Head of Bus. Devel. & Member of Advisory Board)

Recognition and Awards
Evaxion Biotech has been awarded the 2019 Nobel Prize for its pioneering work in the field of cancer research. We were also awarded the Wallenberg Prize for Excellence in Medical Research in 2020.
References

https://in.investing.com/equities/evaxion-biotech-as-drc-o

https://finance.yahoo.com/quote/EVAX/profile?p=EVAX

https://www.crunchbase.com/organization/evaxion-biotech

https://www.evaxion-biotech.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Evaxion Biotech
Leadership team

Dr. Niels Iversen Moeller M.D. (Co-Founder, VP of Bus. & Director)

Mr. Andreas Holm Mattsson (Co-Founder and Chief AI & Culture Officer)

Dr. Birgitte Rono Ph.D. (Chief Scientific Officer)

Products/ Services
Biotechnology
Number of Employees
50 - 100
Headquarters
Copenhagen, Hovedstaden, Denmark
Established
2008
Company Registration
SEC CIK number: 0001828253
Traded as
NASDAQ:EVAX
Social Media
URL
https://www.evaxion-biotech.com